Top Markets
Coin of the day
Wuhan Hiteck Biological Pharma Co.,Ltd Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd

300683
Clasificación en acciones #13466
Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise... Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise operating in China, primarily engaged in the research, development, manufacturing, and commercialization of bio-engineered products and lyophilized injectable medications. The company's extensive product portfolio encompasses a variety of pharmaceutical solutions, such as Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye acyclovir tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository; Xunkeyuan tinidazole suppository; and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck also provides a comprehensive array of diagnostic kits. These include tests for measles virus and rubella virus nucleic acid, mycoplasma isolation and identification, bacterial vaginosis rapid detection, measles virus IgG antibodies, and the coronavirus N-protein. Furthermore, the firm supplies active pharmaceutical ingredients (APIs) and their chemical intermediates, notably Lopinavir and Ritonavir. Its core therapeutic areas of focus are the nervous system and oncology. Established in 1992, Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in Wuhan, China.
Precio por acción
$3.71
Capitalización bursátil
$486.16M
Cambio (1 día)
-0.97%
Cambio (1 año)
-45.64%
País
CN
Comercio Wuhan Hiteck Biological Pharma Co.,Ltd (300683)

Categoría

Ganancias de Wuhan Hiteck Biological Pharma Co.,Ltd (300683)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Wuhan Hiteck Biological Pharma Co.,Ltd, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Wuhan Hiteck Biological Pharma Co.,Ltd desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras